Acular is the ophthalmic formulation of ketorolac tromethamine, designed specifically for short‑term reduction of pain and inflammation in the eyes. As a 0.5% ophthalmic solution, it delivers the same active molecule found in systemic ketorolac products but with localized action and minimal systemic exposure. Acular is commonly used after ophthalmic procedures, including cataract surgery, and may also be applied for temporary relief of symptoms associated with allergic conjunctivitis.
This page provides a scientific overview of Acular, its mechanism, clinical applications, and formulation characteristics. For broader pharmacological context, see the Ketorolac tromethamine page, and for systemic forms visit the Toradol overview.
Acular is the ophthalmic formulation of ketorolac tromethamine, designed for localized short‑term reduction of ocular pain and inflammation. It is supplied as a 0.5% ophthalmic solution, delivering the same active molecule used in systemic ketorolac products but with minimal systemic absorption. The tromethamine salt is used because it significantly improves solubility and stability, allowing ketorolac to be formulated as a clear, fast‑acting eye drop. Unlike oral or injectable forms, Acular acts directly on ocular tissues, providing targeted relief without systemic exposure.
Acular belongs to the NSAID class and functions as a topical non‑opioid analgesic and anti‑inflammatory agent. It inhibits prostaglandin synthesis in ocular tissues, reducing inflammation, discomfort, and postoperative irritation. While systemic ketorolac is used for acute moderate to severe pain, the ophthalmic form is optimized for eye‑specific conditions such as postoperative inflammation or allergic conjunctivitis. Its mechanism is identical to systemic ketorolac, but its localized delivery ensures a favorable safety profile for ophthalmic use.
Acular reduces ocular pain and inflammation by inhibiting prostaglandin synthesis within the eye. Prostaglandins are key mediators of inflammation, contributing to redness, swelling, and discomfort after surgical procedures or allergic reactions. By blocking COX‑1 and COX‑2 enzymes in local tissues, Acular decreases prostaglandin levels directly at the site of irritation.
This localized inhibition leads to reduced inflammation, less tearing, and diminished discomfort. Because the drug acts topically, systemic absorption is minimal, making it suitable for short‑term ophthalmic use.
Unlike steroid eye drops, which suppress a broad range of inflammatory pathways, Acular targets prostaglandins specifically. This provides anti‑inflammatory benefits without the steroid‑related risks such as increased intraocular pressure or delayed wound healing. Acular’s mechanism is similar to systemic ketorolac, but its localized delivery ensures a faster onset in ocular tissues. More details on timing characteristics are available on the Toradol onset & duration page.
Acular is commonly used after ophthalmic procedures, including cataract extraction and corneal surgeries, to reduce postoperative inflammation and discomfort. Its fast‑acting NSAID mechanism helps stabilize irritation during the early recovery period.
It may also be used after LASIK or PRK procedures to manage temporary postoperative pain. Although these procedures typically involve minimal discomfort, Acular can help reduce irritation during the initial healing phase.
Acular is also applied for allergic conjunctivitis, where prostaglandin‑mediated inflammation contributes to itching, redness, and tearing. By reducing prostaglandin activity, Acular helps alleviate these symptoms.
In some cases, Acular may be used for temporary relief of ocular pain caused by minor trauma or irritation. More general pain‑related information is available on the Toradol for pain page.
Acular 0.5% is the standard ophthalmic formulation of ketorolac tromethamine, used for postoperative inflammation and temporary relief of ocular discomfort. It provides rapid onset and localized anti‑inflammatory action.
Acular LS is a lower‑strength formulation designed to reduce stinging upon instillation. It is often used in patients who require gentler application or have heightened ocular sensitivity. Despite the lower concentration, it delivers similar localized effects.
Acuvail is a preservative‑free formulation of ketorolac ophthalmic solution. It is designed for patients who require preservative‑free therapy, such as those with dry eye syndrome or sensitivity to benzalkonium chloride. Acuvail provides the same active molecule but with enhanced tolerability.
All formulations share the same mechanism of action but differ in concentration, tolerability, and intended use scenarios.
Acular has a fast onset because ophthalmic solutions deliver the active molecule directly to the affected tissues. The cornea and conjunctiva absorb ketorolac rapidly, allowing the drug to begin reducing prostaglandin levels within a short time after instillation.
Compared with systemic forms such as oral tablets or injections, ophthalmic ketorolac acts more quickly in the eye because it bypasses systemic distribution. Systemic onset details are available on the Toradol onset & duration page.
This rapid onset makes Acular suitable for postoperative irritation, allergic conjunctivitis, and short‑term ocular discomfort.
The duration of Acular is relatively short because ophthalmic solutions are cleared naturally through tear drainage and blinking. Although the drug acts quickly, its effect diminishes as the concentration in ocular tissues decreases.
This short duration is typical for topical NSAIDs and explains why repeated application is often required for sustained relief. The localized nature of the drug ensures that systemic exposure remains minimal while providing targeted anti‑inflammatory action.
Acular (ketorolac ophthalmic) is one of several NSAID eye drop options. Compared with diclofenac ophthalmic, Acular provides similar anti‑inflammatory effects but is often preferred for postoperative pain due to its strong prostaglandin inhibition.
Nepafenac is a prodrug that converts to amfenac within ocular tissues. It may offer deeper penetration into intraocular structures, making it useful for certain postoperative scenarios. However, Acular remains widely used due to its established efficacy and predictable onset.
Bromfenac is another ophthalmic NSAID with high lipophilicity, allowing strong tissue penetration. It is often used for postoperative inflammation but may be more expensive.
Ketorolac is typically chosen for its balance of potency, rapid onset, and broad clinical availability across multiple formulations.
Acular (ketorolac ophthalmic) differs from steroid eye drops in both mechanism and safety profile. As an NSAID, Acular works by inhibiting prostaglandin synthesis in ocular tissues, reducing inflammation, pain, and postoperative irritation. Steroid drops, by contrast, suppress a broader range of inflammatory pathways, including cytokines and cellular immune responses, making them more potent but also more complex in their effects.
The risk profiles also differ significantly. Acular does not raise intraocular pressure and does not slow corneal healing, which makes it suitable for short‑term use after procedures or during episodes of allergic conjunctivitis. Steroid drops may increase intraocular pressure, elevate the risk of steroid‑induced glaucoma, delay epithelial healing, and increase susceptibility to infections.
NSAID drops like Acular are typically chosen for mild to moderate postoperative inflammation, ocular discomfort, or allergy‑related irritation. Steroid drops are selected when inflammation is more severe or when deeper suppression of inflammatory pathways is required. The choice depends on the intensity of inflammation and the clinical context.
Acular may cause local ocular reactions, which are typical for topical NSAID eye drops. The most common effects include temporary burning, stinging, or mild irritation immediately after instillation. These sensations are usually short‑lived and related to the interaction of the solution with the corneal surface.
Additional local reactions may include redness, tearing, a sensation of dryness, or the feeling of a foreign body in the eye. These effects reflect localized irritation rather than systemic exposure. Because Acular acts topically, systemic absorption is minimal, and systemic NSAID‑related side effects are extremely rare.
Compared with oral or injectable ketorolac, Acular does not carry risks of gastrointestinal irritation, renal stress, or systemic bleeding. Its safety profile is largely confined to the ocular surface, making it suitable for short‑term postoperative or inflammatory use.
Rarely, more pronounced reactions may occur, such as increased sensitivity to light or prolonged irritation. In such cases, alternative ophthalmic formulations may be considered.
Acular is contraindicated in individuals with hypersensitivity to ketorolac, other NSAIDs, or any component of the formulation. Patients with known aspirin sensitivity or a history of NSAID‑induced allergic reactions should avoid its use.
Caution is required in patients with compromised corneal integrity, as topical NSAIDs may slow epithelial healing. Individuals with dry eye syndrome, corneal erosions, or recent complex ocular surgery may require gentler or preservative‑free formulations such as Acuvail.
Drug interactions are minimal because systemic absorption is low. However, combining multiple topical NSAIDs is generally avoided due to the risk of increased irritation. Concurrent use with steroid eye drops requires monitoring of corneal healing.
| Form | Concentration | Features | Use |
|---|---|---|---|
| Acular | 0.5% | Standard formulation | Pain / inflammation |
| Acular LS | 0.4% | Gentler on the eye | Post‑procedure comfort |
| Acuvail | 0.45% | Preservative‑free | Post‑surgical use |
All formulations contain ketorolac but differ in concentration, tolerability, and intended use. Acular is the standard option for postoperative discomfort and inflammation. Acular LS reduces stinging upon instillation, while Acuvail offers a preservative‑free alternative suitable for sensitive eyes or post‑surgical recovery.
| Medication | Strength | Speed | Risks | Used For |
|---|---|---|---|---|
| Acular | Medium | Fast | Low | Pain / inflammation |
| Diclofenac ophthalmic | Medium | Medium | Medium | Inflammation |
| Nepafenac | High | Medium | Medium | Post‑surgical use |
Acular provides a strong balance of speed and safety, making it suitable for postoperative discomfort and allergic inflammation. Diclofenac ophthalmic is often used for inflammatory conditions, while nepafenac offers deeper tissue penetration and is commonly selected for post‑surgical inflammation control.
| Medication | Mechanism | Strength | Risks | Used For |
|---|---|---|---|---|
| Acular | NSAID | Medium | Low | Pain / inflammation |
| Steroid drops | Steroid | High | Higher | Severe inflammation |
Acular offers moderate anti‑inflammatory strength with a low risk profile, making it ideal for postoperative discomfort and allergy‑related irritation. Steroid drops provide stronger inflammation control but require caution due to risks such as elevated intraocular pressure and delayed corneal healing. The choice depends on the severity of inflammation.